Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
DX1R7K
|
||||
Drug Name |
(S)-N-(3-(3-(1,3,4-oxadiazol-2-yl)phenyl)-1-(cyanomethylamino)-1-oxopropan-2-yl)benzamide
|
||||
Synonyms |
CHEMBL564626
|
||||
Indication | Discovery agent | Investigative | [1587926] | ||
Formula |
C20H17N5O3
|
||||
Canonical SMILES |
O=C(NCC#N)[C@H](Cc1cccc(c1)c2ocnn2)NC(=O)c3ccccc3
|
||||
InChI |
InChI=1S/C20H17N5O3/c21-9-10-22-19(27)17(24-18(26)15-6-2-1-3-7-15)12-14-5-4-8-16(11-14)20-25-23-13-28-20/h1-8,11,13,17H,10,12H2,(H,22,27)(H,24,26)/t17-/m0/s1
|
||||
InChIKey |
ZRKTXOUQLJMAQT-KRWDZBQOSA-N
|
||||
Target and Pathway | |||||
Target(s) | Cathepsin K | Target Info | [1587926] | ||
Cathepsin L | Target Info | [1587926] | |||
Reactome | Collagen degradation | ||||
Degradation of the extracellular matrix | |||||
Activation of Matrix Metalloproteinases | |||||
Trafficking and processing of endosomal TLR | |||||
MHC class II antigen presentationR-HSA-1236977:Endosomal/Vacuolar pathway | |||||
Assembly of collagen fibrils and other multimeric structures | |||||
MHC class II antigen presentation | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.